Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer

نویسندگان

  • Jie-Tao Ma
  • Jia-He Zheng
  • Cheng-Bo Han
  • Qi-Yong Guo
چکیده

The purpose of this meta-analysis was to compare higher dose (≥30 Gy) and lower dose (<30 Gy) radiotherapy (RT) on palliation of symptoms and survival in patients with locally advanced lung cancer. A search of PubMed and Google Scholar was conducted on 10 June 2013 using combinations of the search terms: radiotherapy, non-small-cell lung carcinoma, palliative, supportive, symptom relief. Inclusion criteria were: (i) palliative thoracic RT; (ii) randomized controlled trial; (iii) English language; and (iv) compared outcomes between higher dose (≥30 Gy) and lower dose (<30 Gy) RT. The primary outcome was palliation of symptoms (cough, chest pain, hemoptysis), and 1- and 2-year overall survival. Tests of heterogeneity, sensitivity, and publication bias were performed. Five randomized controlled trials with a total of 1730 patients with lung cancer were included in the meta-analysis. There were 925 patients treated with a higher RT dose (≥30 Gy) and 805 treated with a lower RT dose (<30 Gy). The combined odds ratios (ORs) indicated no significant difference in palliation of cough, chest pain, and hemoptysis between the higher dose and lower dose RT groups (combined ORs = 0.88, 1.83, 1.39, respectively). The 1- and 2-year OS rates were similar between the high and low dose RT groups (combined ORs = 1.09 and 1.38, respectively). This meta-analysis indicates that high dose (≥30 Gy) and lower dose (<30 Gy) RT provide similar symptom palliation and 1- and 2-year OS in patients with locally advanced lung cancer.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Response to “A meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer”

Response to " A meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer " D ear Editor, We have read the Letter to the Editor by Vlayen et al. carefully. We apologize for the wrongly extracted data in our meta-analysis. (1) The 1-year overall survival (OS) rate in the Dutch trial by Kramer et al. (2) was 19.6% for the high-dose group and 10.9% f...

متن کامل

Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer

D ear Editor, In the context of an update of the Dutch guideline on non-small-cell lung cancer, we performed a systematic review on the clinical effectiveness of low-dose (i.e. <30 Gy) versus high-dose palliative radiotherapy (i.e. ≥30 Gy). We identified the recent meta-analysis of Ma et al. that included five randomized trials published until June 2013. Our systematic review confirmed the comp...

متن کامل

Comparing different techniques of Post Axillary field in Breast Cancer Treatment

As we know breast cancer is the second death reason in Iran. One step of treatment process is radiotherapy, which needs careful consideration of contouring and therapeutic techniques Lung, thyroid, spinal cord, trachea and humerus are sensitive organs in breast cancer radiation therapy.  The most clinical studies recommended two ways for delivering 95 percent of dose to supraclavicular and ...

متن کامل

Concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: a retrospective analysis of the correlation between radiotherapy-related factors and tumor response

Background: To determine which radiotherapy parameters are associated with the tumor response of locally advanced non-small cell lung cancer (NSCLC) patients undergoing concurrent chemoradiotherapy. Materials and Methods: Thirty one patients with IIIA/IIIB NSCLC underwent chemoradiotherapy with a median dose of 63 Gy. On our actual treatments, we made radiotherapy planning to cover the planning...

متن کامل

REVIEW SERIES Lung cancer v 5: State of the art radiotherapy for lung cancer

Radiotherapy is the most commonly used treatment modality for patients with lung cancer in the UK, with established, although frequently ignored, indications. It has a role in early, medically inoperable, and locally advanced unresectable non-small cell lung cancer (NSCLC), where some patients are cured, in the palliation of advanced lung cancer of all types, and in the adjuvant treatment of li...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 105  شماره 

صفحات  -

تاریخ انتشار 2014